Soleno Therapeutics (SLNO) Invested Capital: 2013-2019
Historic Invested Capital for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $14.9 million.
- Soleno Therapeutics' Invested Capital rose 4.79% to $14.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.9 million, marking a year-over-year increase of 4.79%. This contributed to the annual value of $30.4 million for FY2018, which is 13.41% up from last year.
- Soleno Therapeutics' Invested Capital amounted to $14.9 million in Q3 2019, which was up 7.53% from $13.8 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Invested Capital registered a high of $30.4 million during Q4 2018, and its lowest value of -$11.3 million during Q1 2015.
- Its 3-year average for Invested Capital is $22.1 million, with a median of $23.2 million in 2017.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 922.53% in 2017, then tumbled by 40.66% in 2018.
- Over the past 5 years, Soleno Therapeutics' Invested Capital (Quarterly) stood at $4.1 million in 2015, then fell by 15.99% to $3.4 million in 2016, then soared by 680.65% to $26.8 million in 2017, then climbed by 13.41% to $30.4 million in 2018, then increased by 4.79% to $14.9 million in 2019.
- Its Invested Capital stands at $14.9 million for Q3 2019, versus $13.8 million for Q2 2019 and $23.6 million for Q1 2019.